CA-UC-DAVIS-HEALTH
A new UC Davis Eye Center study , in collaboration with France’s INSERM Stem Cell and Brain Research Institute , found that special patented glasses engineered with technically advanced spectral notch filters enhance color vision for those with the most common types of red-green color vision deficiency (“anomalous trichromacy”). Notably, the ability to identify and experience expanded color was also demonstrated when color blind test subjects were not wearing the glasses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200713005065/en/
At least eight in 100 men (8%) and one in 200 women (0.5%) suffer from red-green color vision deficiency (CVD), totaling 13 million in the U.S. and 350 million worldwide. While those with normal color vision see in excess of one million hues and shades, the CVD see a vastly diminished range of colors. People with CVD experience colors as more muted and washed out, and some colors cause confusion or are more difficult to differentiate. With an undergraduate and graduate student body of nearly 40,000, UC Davis has an estimated 1,700 students with red-green CVD.
The study evaluated the impact of spectral notch filters on enhancing the chromatic responses of observers with red-green CVD over two weeks of usage. The filters (EnChroma glasses) are designed to increase the separation between color channels to help people with color blindness see colors more vibrantly, clearly and distinctly.
The research, published in Current Biology , had CVD participants wear the special filter glasses or placebo glasses. Over two weeks, they kept a diary and were re-tested on days 2, 4 and 11 but without wearing the glasses. The researchers found that wearing the filter glasses increased responses to chromatic contrast response in individuals with red-green color blindness. It is unclear how long the improvement lasts without wearing the filters, but the evidence shows that the effect persists for some time.
“Extended usage of these glasses boosts chromatic response in those with anomalous trichromacy (red-green color vision deficiency),” said John S. Werner , distinguished professor of ophthalmology and a leader in vision science at UC Davis Health. “We found that sustained use over two weeks not only led to increased chromatic contrast response, but, importantly, these improvements persisted when tested without the filters, thereby demonstrating an adaptive visual response.”
Werner noted that this effect cannot be achieved with broad-band filters sold as aids to the color blind. He and his research colleagues believe the study’s findings suggest that modifications of photoreceptor signals activate a plastic post-receptoral substrate in the brain that could potentially be exploited for visual rehabilitation.
“When I wear the glasses outside, all the colors are extremely vibrant and saturated, and I can look at trees and clearly tell that each tree has a slightly different shade of green compared to the rest," said Alex Zbylut, one of the color blind participants in the study who got the placebo glasses first and then tried the special filter version afterwards. "I had no idea how colorful the world is and feel these glasses can help color blind people better navigate color and appreciate the world."
Reactions from other participants about their experiences with the glasses can be found in the Supplement section of the Current Biology article.
Werner, lead author of the study, has published numerous scholarly works and was awarded the prestigious 2015 Verriest Medal from the International Colour Vision Society.
Co-authors on the study, Adaptive Changes in Color Vision from Long-Term Filter Usage in Anomalous but Not Normal Trichromacy , include Kenneth Knoblauch of the Université de Lyon and Inserm Stem Cell and Brain Research Institute in France, and Brennan Marsh-Armstrong, a medical student now at UC San Diego. The research was supported by the National Eye Institute and grants from LABEX CORTEX, Universite de Lyon, operated by the French National Research Agency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200713005065/en/
Social Media:
https://www.facebook.com/UCDavisEyeCenter/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MultiBank Group Confirms $MBG Token TGE Set for July 22, 202512.7.2025 11:14:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250712404220/en/ MultiBank Group has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This milestone will mark the full activation of the $MBG Token on the blockchain, enabling holders to view and manage their balances across supported platforms. Following the token minting, users will be able to trade $MBG via MultiBank.io, the Group’s regulated crypto exchange and Uniswap, the world’s leading decentralized platform. The $MBG Token has garnered global attention for its rare combination of real-world utility, institutional backing, and strong deflationary mechanics. It is underpinned by $29 billi
Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics11.7.2025 14:00:00 CEST | Press release
Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). The pilot marks another step toward making PCTs more accessible, timely, and scalable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711152688/en/ As late-stage PCT clinical trials progress and therapy developers work to create the next generation of PCTs, the speed, reliability, scaling and cost of traditional production methods pose a major challenge. Specifically, the first step of DNA template production is hi
$MBG Token Pre-Sale Set for July 15 — Only 7 Million Tokens Available at $0.3511.7.2025 10:17:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution headquartered in Dubai, has confirmed that its highly anticipated $MBG Token pre-sale will go live on July 15, with demand expected to be intense. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711737311/en/ With only 7 million $MBG tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. With only 7 million tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. Early participants can join simultaneously on MultiBank.io, the Group’s regulated crypto exchange, and Uniswap, the world’s leading decentralized platform. Supported by $29 billion in real assets and powered by over $35 billion in daily turnover, $MBG is engineered
Live Story Raises €2.7 Million to Revolutionize the Digital Experience11.7.2025 10:05:00 CEST | Press release
With a round led by Vertis, the next-generation CMS platform accelerates its focus onAI, performance, and European expansion. Target: surpass €10M in recurring revenueby 2027. Live Story, the tech company founded by Stefano Mocellini, has closed a €2.7 million seed round led by Vertis, one of Italy’s leading early-growth venture capital firms. The funding will support the company’s international expansion and technological development, with a clear goal: to exceed €10 million in annual recurringrevenue by 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711335560/en/ “We invested in Live Story because it addresses one of the major inefficiencies in digital commerce: the slow and rigid management of visual and narrative content,” says Alessandro Pontari, Partner at Vertis SGR. “The platform helps brands drastically reduce their time-to-market through a visual CMS that integrates seamlessly with any tech stack. In a wor
With a Score of 84 out of 100, Sagemcom Is Awarded the EcoVadis Platinum Medal: a Prestigious Recognition of its CSR Commitment11.7.2025 09:00:00 CEST | Press release
Sagemcom Group is proud to announce that it has been awarded, for the third time, the Platinum Medal by EcoVadis, the highest distinction granted by the leading global platform for assessing Corporate Social Responsibility (CSR) performance. This medal places Sagemcom in the top 1% of companies evaluated worldwide, across all industries. With a score of 84 out of 100, Sagemcom reaffirms its position as a committed leader in ecological transition, business ethics, sustainable supply chain management, and social responsibility. “The EcoVadis Platinum Medal is more than just an award — it is the recognition of our collective efforts to embed sustainable development principles at the heart of our corporate strategy and culture,” says Sylvaine Couleur, Executive Vice President, CSR & Communication. “Achieving this level demonstrates that our commitments are tangible, impactful, and internationally recognized. This distinction strengthens our determination to further advance and expand our C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom